Education
About Us
Working with TipRanks
Follow Us
Synlogic (DE:MIN)
MUNICH:MIN
MIN Stock Chart & Stats
€1.45
€0.00(0.00%)
At close: 4:00 PM EST
€1.45
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€1.34 - €1.45
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€7.23M
Enterprise Value-€6.30M
Total Cash (Recent Filing)€14.67M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.56
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,698,919
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.16
Price to Sales (P/S)0.00
P/FCF Ratio-3.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Zero DebtHaving zero reported debt in 2024–2025 materially lowers refinancing and interest-rate risk for a clinical-stage biotech. This preserves flexibility to prioritize R&D and partnerships rather than servicing debt, extending the firm's strategic options while it pursues clinical programs.
Substantially Reduced Cash Burn In 2025A marked reduction in operating cash outflows in 2025 indicates meaningful cost discipline or program reprioritization. Lower burn improves runway and reduces near-term financing needs, making the company less dependent on frequent capital raises while it advances clinical milestones.
Platform-based Clinical-stage PipelineSynlogic's engineered-microbe platform targets metabolic and immunology indications, creating program optionality from a single technology base. A platform approach increases long-term upside via multiple programs or partnerships and supports durable scientific differentiation in synthetic biology.
Bears Say
Nasdaq Suspension And Delisting To OTCDelisting from Nasdaq and a shift to OTC materially reduces liquidity, market visibility, and institutional participation. That structural change raises long-term cost of capital, complicates equity raises and partnerships, and can impede commercial credibility for a clinical-stage biotech.
Minimal, Volatile Revenue And No Product SalesThe absence of recurring commercial revenue means the business lacks operating leverage and dependably cash-generative products. Sustained R&D and trials will therefore rely on external funding, making long-term program advancement sensitive to capital markets and dilutive financing.
Eroding Shareholder EquityA shrinking equity base reflects cumulative losses and reduces the balance-sheet buffer to absorb future setbacks. This deterioration limits financial flexibility, increases dilution risk in future financings, and narrows options for pursuing costly clinical development paths.
Synlogic News
MIN FAQ
What was Synlogic’s price range in the past 12 months?
Synlogic lowest stock price was €1.34 and its highest was €1.45 in the past 12 months.
What is Synlogic’s market cap?
Synlogic’s market cap is €7.23M.
When is Synlogic’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Synlogic’s earnings last quarter?
Currently, no data Available
Is Synlogic overvalued?
According to Wall Street analysts Synlogic’s price is currently Overvalued.
Does Synlogic pay dividends?
Synlogic does not currently pay dividends.
What is Synlogic’s EPS estimate?
Synlogic’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Synlogic have?
Synlogic has 11,698,919 shares outstanding.
What happened to Synlogic’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Synlogic?
Currently, no hedge funds are holding shares in DE:MIN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Synlogic
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
Technical Analysis
Lisata Therapeutics
―
Aptevo Therapeutics
―
SeaStar Medical Holding
―
Cingulate Inc
―
Allarity Therapeutics
―
Options Prices
Currently, No data available
---